XFOR — X4 Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $317.27m
- $186.06m
- $35.11m
Brief: X4 Pharmaceuticals And Norgine Enter Into Exclusive Licensing Agreement To Commercialize Mavorixafor In Europe, Australia, And New Zealand
Brief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Cisco, Freshpet, Nvidia
X4 Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: X4 Pharmaceuticals Reports Q3 2024 Financial Results And Provides Corporate Update
Brief: X4 Pharmaceuticals reports positive results from completed six-month phase 2 trial of Mavorixafor
Brief: X4 Pharmaceuticals Q3 EPS USD -0.18 Vs. IBES Estimate USD -0.17
X4 Pharmaceuticals Inc expected to post a loss of 17 cents a share - Earnings Preview
X4 Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: X4 Pharmaceuticals Q2 EPS USD 0.45 Vs. IBES Estimate USD 0.01
X4 Pharmaceuticals Inc expected to post earnings of 1 cent a share - Earnings Preview
Brief: X4 Pharmaceuticals Announces $125 Million Capital Infusion From $105 Million Sale Of Priority Review Voucher And $20 Million Drawdown From Existing Loan Facility
X4 Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: X4 Pharmaceuticals Q1 EPS USD -0.26 Vs. IBES Estimate USD -0.16
X4 Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
X4 Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-3M, Phibro Animal Health, copper miners
U.S. STOCKS ON THE MOVE-Revvity, Southern Co, Duke Energy
U.S. STOCKS ON THE MOVE-Fulton, Deciphera Pharmaceuticals, VivoPower